- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06412848
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
May 23, 2024 updated by: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
A Multicenter, Retrospective, Observational Study of Avelumab Maintenance and Subsequent Therapies in Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma
This study is a multicenter, non-interventional, retrospective, medical chart review of locally advanced or metastatic (la/m) Urothelial Cancer UC participants who were prescribed avelumab as first line maintenance therapy after a platinum-based chemotherapy.
This study aims to understand the index date (i.e., at the initiation of avelumab maintenance therapy) demographics and clinical characteristics of participants with locally advanced/metastatic Urothelial Carcinoma in Japan, and to describe their treatment patterns and outcomes.
Study Overview
Study Type
Observational
Enrollment (Estimated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Communication Center
- Phone Number: +49 6151 72 5200
- Email: service@emdgroup.com
Study Locations
-
-
-
Akita, Japan, 010-0041
- Not yet recruiting
- Akita University Hospital
-
Fukuoka, Japan, 811-1347
- Recruiting
- Kyushu Cancer Center
-
Kumamoto, Japan, 860-8556
- Not yet recruiting
- Kumamoto University Hospital
-
Kyoto, Japan, 606-8507
- Not yet recruiting
- Kyoto University Hospital
-
Kyoto, Japan, 602-8566
- Not yet recruiting
- University Hospital Kyoto Prefectural University of Medicine
-
Osaka, Japan, 540-0008
- Recruiting
- Osaka International Cancer Institute
-
Tokushima, Japan, 770-0042
- Not yet recruiting
- Tokushima University Hospital
-
Toyama, Japan, 930-0194
- Not yet recruiting
- Toyama University Hospital
-
Yamagata, Japan, 9902331
- Recruiting
- Yamagata University Hospital
-
-
Aomori
-
Hirosaki, Aomori, Japan, 036-8563
- Not yet recruiting
- Hirosaki University Hospital
-
-
Ehime
-
Toon, Ehime, Japan, 791-0295
- Not yet recruiting
- Ehime University Hospital
-
-
Fukuoka
-
Kurume, Fukuoka, Japan, 830-0011
- Not yet recruiting
- Kurume University Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8648
- Not yet recruiting
- Hokkaido University Hospital
-
Sapporo, Hokkaido, Japan, 060-8648
- Not yet recruiting
- Sapporo Medical University Hospital
-
-
Hyogo
-
Kobe, Hyogo, Japan, 650-0017
- Recruiting
- Kobe University Hospital
-
-
Iwate
-
Shiwa-gun, Iwate, Japan, 028-3695
- Not yet recruiting
- Iwate Medical University Hospital
-
-
Kagawa
-
Kita-gun, Kagawa, Japan, 761-0793
- Recruiting
- Kagawa University Hospital
-
-
Kanagawa
-
Kawasaki, Kanagawa, Japan, 216-8511
- Not yet recruiting
- St. Marianna University Hospital
-
Sagamihara, Kanagawa, Japan, 252-0374
- Not yet recruiting
- Kitasato University Hospital
-
-
Nara
-
Kashihara, Nara, Japan, 634-8522
- Recruiting
- Nara Medical University Hospital
-
-
Osaka
-
Osakasayama, Osaka, Japan, 589-8511
- Not yet recruiting
- Kindai University Hospital
-
-
Saitama
-
Hidaka, Saitama, Japan, 350-1298
- Not yet recruiting
- Saitama Medical University International Medical Center
-
-
Tokya
-
Bunkyo-ku, Tokya, Japan, 113-0033
- Not yet recruiting
- Juntendo University Hospital
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8603
- Not yet recruiting
- Nippon Medical School Hospital
-
Chuo-ku, Tokyo, Japan, 104-0045
- Not yet recruiting
- National Cancer Center Hospital
-
Itabashi-ku, Tokyo, Japan, 173-8606
- Not yet recruiting
- Teikyo University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Participants with locally advanced/metastatic Urothelial Carcinoma
Description
Inclusion Criteria:
- Participants diagnosed with locally advanced/metastatic urothelial carcinoma (la/m UC) before receiving avelumab first line maintenance therapy
- Participants with la/m UC (irrespective of tumor histology) whose disease has not progressed (ongoing stable disease, partial response, or complete response) following completion of first line PBCT and who has been treated with avelumab
- Participants who has been started avelumab first line maintenance therapy for la/m UC from 24 Feb 2021 (date of approval for UC) to 6 months before the date of approval of implementation of this study at each site
- Participants aged >= 18 years old at index date
- Other protocol defined inclusion criteria could apply
Exclusion Criteria:
- Participant participated in a clinical trial in la/m UC during the study periods.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Urothelial Carcinoma Cohort
This is a single cohort study enrolling Participants with Urothelial Carcinoma (UC), who are prescribed treatment with avelumab as first line maintenance therapy after a platinum-based chemotherapy (PBCT).
|
This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline clinical and demographic characteristics
Time Frame: Baseline
|
To describe the baseline clinical and demographic characteristics of participants.
|
Baseline
|
Characteristics of the first line PBCT just prior to avelumab maintenance
Time Frame: Up to 3 months
|
Up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival (OS)
Time Frame: Up to 3 months
|
Up to 3 months
|
Progression-Free Survival (PFS)
Time Frame: Up to 3 months
|
Up to 3 months
|
Time to Treatment Failure (TTF)
Time Frame: Up to 3 months
|
Up to 3 months
|
Time to Next Treatment (TTNT)
Time Frame: Up to 3 months
|
Up to 3 months
|
Objective Response Rate (ORR)
Time Frame: Up to 3 months
|
Up to 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Medical Responsible, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 9, 2024
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
July 31, 2024
Study Registration Dates
First Submitted
April 23, 2024
First Submitted That Met QC Criteria
May 10, 2024
First Posted (Actual)
May 14, 2024
Study Record Updates
Last Update Posted (Actual)
May 24, 2024
Last Update Submitted That Met QC Criteria
May 23, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MS100070_0209
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial CarcinomaUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); ExelixisRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation | Infiltrating Bladder Urothelial Carcinoma With Squamous... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial CarcinomaUnited States
-
Stanford UniversityAstraZenecaTerminatedBladder Adenocarcinoma | Bladder Mixed Adenocarcinoma | Bladder Squamous Cell Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Giant Cells | Infiltrating Bladder Urothelial Carcinoma, Nested Variant | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Bladder Urothelial... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnInfiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial CarcinomaUnited States
Clinical Trials on Avelumab
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Clinique Neuro-OutaouaisCompletedGlioblastoma Multiforme of BrainCanada
-
Promontory Therapeutics Inc.Pfizer; EMD SeronoCompletedNon-Small Cell Lung Cancer (NSCLC)United States, Switzerland
-
Vaccinex Inc.University of RochesterRecruitingMetastatic Pancreatic AdenocarcinomaUnited States
-
Samsung Medical CenterMerck KGaA, Darmstadt, GermanyActive, not recruitingLymphoma, Extranodal NK-T-CellKorea, Republic of
-
Merck KGaA, Darmstadt, GermanyCompletedSolid TumorsGermany
-
AHS Cancer Control AlbertaEMD Serono; Alberta Cancer FoundationRecruitingSquamous Cell Carcinoma of the SkinCanada
-
McGill University Health Centre/Research Institute...RecruitingGastric Adenocarcinoma | Esophageal AdenocarcinomaCanada
-
4SC AGMerck KGaA, Darmstadt, GermanyWithdrawn
-
PfizerTerminatedUrinary Bladder Neoplasms | Bladder Cancer | Urothelial Carcinoma | Bladder TumorsCanada